FDA expands pediatric indication for entrectinib and approves new pellet formulation

Coverage, in order

1. 1d ago
   FDA Drug Safety / Drugs feed indie

   FDA expands pediatric indication for entrectinib and approves new pellet formulation

   On October 20, 2023, the Food and Drug Administration granted accelerated approval to entrectinib (Rozlytrek, Genentech Inc.) for pediatric patients older than 1 month with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.